View Clinical Trial (Medical Research Study)

Smoking Interventions for Hospital Patients: A Comparative Effectiveness Trial

This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Browse Studies

City:   Boston
State:   Massachusetts
Zip Code:   02114
Conditions:   Cigarette Smoking
Purpose:   Cigarette smoking is the leading preventable cause of death in the U.S. Nearly 4 million U.S. smokers are hospitalized each year, many of them at high risk for tobacco-related disease or death. A hospital admission provides an opportunity for a smoker to quit. Smoking cessation counseling provided in the hospital is effective, but only if it continues for >1 month after discharge. Smoking cessation medications add benefit to counseling but are not often used. The challenge is to translate this efficacy research into routine clinical practice. The major barrier is to make the transition from inpatient to outpatient care. An evidence-based, cost-effective intervention model that can be adopted by U.S. hospitals is needed to realize the potential impact of hospital smoking interventions. The Specific Aim of this project is to conduct a randomized controlled comparative effectiveness trial of two strategies to promote smoking cessation in hospitalized patients: (1) a hospital-only intervention that meets the current standard of the National Hospital Quality Measures("Standard Care"), and (2) an "Extended Care Management" model with 2 components that aims to encourage and facilitate the sustained use of smoking cessation treatment (counseling and medication use) after discharge in order to achieve long-term abstinence. It adds to Standard Care 3 months of telephone-based contact after discharge and feature 2 innovations: (1) to increase medication use, smokers willing to make a quit attempt receive a free, refillable 30-day sample of their choice of FDA-approved smoking cessation medication at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers interested in or most likely to benefit from continued counseling after discharge. The trial will enroll 330 adult smokers admitted to Massachusetts General Hospital, a 900-bed teaching hospital. Outcomes will be measured 1,3 and 6 months after hospital discharge. Study hypotheses are that the enhanced care arm, compared to usual care, is feasible and will increase (1) the use of smoking cessation treatment after discharge, (2) the duration of post-discharge tobacco abstinence, and (3) validated tobacco abstinence 6 months after hospital discharge (primary outcome). The principal secondary outcome measure is self-reported 7-day point prevalence tobacco abstinence after hospital discharge. Other secondary endpoints include self-reported point prevalence abstinence at 1 and 3 months, prolonged abstinence (self-reported tobacco abstinence at 1, 3, and 6 months). The cost-effectiveness (cost per quit) of the interventions will be also be compared.
Study Summary:  
Criteria:   Inclusion Criteria: - Cigarette smoker (daily smoker when smoking in usual way during the month before hospital admission) - Counseled by hospital smoking counselor during hospital stay - Plans to stop smoking tobacco products after hospital discharge - Appropriate for use of smoking cessation medication after discharge Exclusion Criteria: - Expected hospital length of stay <24 hours - Not expected to be discharged to home - No access to a telephone - Unable to communicate by telephone - Severe psychiatric or neurologic disease precluding ability to be counseled - Pregnant, nursing, or planning to become pregnant in next 3 months - Active substance abuse other than tobacco - Unable to speak English
NCT ID:   NCT01177176
Primary Contact:   Principal Investigator
Nancy A Rigotti, MD
Massachusetts General Hospital

Backup Contact:   N/A
Location Contact:   Boston, Massachusetts 02114
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:
Date Processed:   August 28, 2014
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


    (updated 9 minutes ago)
Within 25 Miles

Pediatric Type 2 Diabetes (Ages 10-17) - Boston MA

Gingivitis - Cambridge MA

Gum Disease - Cambridge MA

Healthy Volunteers (Weighing less than 175 lbs) - Boston MA

Healthy Volunteers (Weighing more than 175 lbs) - Boston MA

Gout with Heart Conditions - Brockton MA

Obsessive Compulsive Disorder (OCD) - Boston MA

Post Herpatic Neuralgia - Brockton MA

Overactive Bladder - Brockton MA

Constipation - Brockton MA

Adolescent Major Depression (Ages 12-17) - Watertown MA

Glaucoma - Quincy MA

Dust Mite Allergy - Brockton MA

Osteoarthritis of Knee - Brockton MA

Diabetic Neuropathy - Brockton MA

Opioid Induced Constipation - Brockton MA

High Cholesterol - Brockton MA

Acne - Brockton MA

Irritable Bowel Syndrome with Diarrhea - Brockton MA

Smoking Cessation (Teens Ages 12 - Watertown MA

High Cholesterol - Brockton MA

Treatment Resistant Depression - Boston MA

Migraines - Brockton MA

Type 2 Diabetes - Brockton MA

Overactive Bladder - Brockton MA

Obsessive Compulsive Disorder (OCD) - Boston MA

Cigarette Smoking - Belmont MA

Diabetic Foot Pain - Greater Boston MA

High Cholesterol - Methuen MA

Healthy Volunteers - Cambridge MA

Migraines - Roslindale MA

Within 50 Miles

Endometriosis - Fall River MA

Endometriosis - Providence RI

Osteoarthritis of the Knee - New Bedford MA

Benign Prostatic Hyperplasia - Warwick RI

Type 2 Diabetes - Nashua NH

Type 1 Diabetes - Nashua NH

High Cholesterol - New Bedford MA

Asthma - North Dartmouth MA

Asthma in Children (Ages 5 - Warwick RI

Asthma - Warwick RI

Asthma - Dartmouth MA

Within 100 Miles

Pediatric Type 2 Diabetes (Ages 10-17) - Portland ME

Multiple Sclerosis - New London CT

Alzheimer's Disease - New London CT